Ensoma has emerged with $70m in series A financing to advance research from Fred Hutchinson and University of Washington.

US-based genomic medicine developer Ensoma launched on Thursday with $70m in series A financing to commercialise research from University of Washington and Fred Hutchinson Cancer Research Center. 5AM Ventures led the round, which also included financial services group Fidelity’s F-Prime Capital unit, Viking Global Investors, Cormorant Asset Management, RIT Capital Partners and Symbiosis II. Life…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.